OBJECTIVE: To characterize the magnitude and the predictors of highly active antiretroviral therapy (HAART) interruption (TI) and to investigate its immunologic and virological consequences. METHODS: Using Concerted Action on Seroconversion to AIDS and Death in Europe data from 8,300 persons with well-documented seroconversion dates, we identified subjects with stable first HAART (for at least 90 days) not initiated during primary infection. A TI was defined as an interruption of all antiretroviral therapy drugs for at least 14 days. RESULTS: Of 1,551 subjects starting HAART, 299 (19.3%) interrupted treatment. Median (interquartile range) duration of the TI was 189 (101-382) days. The cumulative probability (95% confidence interval) of TI at 2 years was 15.9% (14.0%-18.1%). Women were more likely to have a TI than men in the same exposure group (35.8% vs 24.2% among drug users, 22.1% vs 13.3% among heterosexuals; P < 0.05). Higher baseline viremia and poor immunologic response to HAART were associated with higher probabilities of TI. Median (interquartile range) individual CD4 cell loss during TI was 94 (1-220) cells/microL. Older age at HAART (>40 yr), lower pre-HAART nadir (<200 cells/microL), and lower CD4 at start of TI (<350 cells/microL) were significantly associated with greater relative CD4 loss during TI. CONCLUSIONS: We estimate that almost 1 in 6 subjects on HAART interrupts treatment by 2 years. Further research is needed to investigate the reasons why TI is higher in women. We have identified characteristics of subjects with the greatest risk for CD4 loss in whom TI may have greater risks.
OBJECTIVE: To characterize the magnitude and the predictors of highly active antiretroviral therapy (HAART) interruption (TI) and to investigate its immunologic and virological consequences. METHODS: Using Concerted Action on Seroconversion to AIDS and Death in Europe data from 8,300 persons with well-documented seroconversion dates, we identified subjects with stable first HAART (for at least 90 days) not initiated during primary infection. A TI was defined as an interruption of all antiretroviral therapy drugs for at least 14 days. RESULTS: Of 1,551 subjects starting HAART, 299 (19.3%) interrupted treatment. Median (interquartile range) duration of the TI was 189 (101-382) days. The cumulative probability (95% confidence interval) of TI at 2 years was 15.9% (14.0%-18.1%). Women were more likely to have a TI than men in the same exposure group (35.8% vs 24.2% among drug users, 22.1% vs 13.3% among heterosexuals; P < 0.05). Higher baseline viremia and poor immunologic response to HAART were associated with higher probabilities of TI. Median (interquartile range) individual CD4 cell loss during TI was 94 (1-220) cells/microL. Older age at HAART (>40 yr), lower pre-HAART nadir (<200 cells/microL), and lower CD4 at start of TI (<350 cells/microL) were significantly associated with greater relative CD4 loss during TI. CONCLUSIONS: We estimate that almost 1 in 6 subjects on HAART interrupts treatment by 2 years. Further research is needed to investigate the reasons why TI is higher in women. We have identified characteristics of subjects with the greatest risk for CD4 loss in whom TI may have greater risks.
Authors: Debika Bhattacharya; T Umbleja; F Carrat; R T Chung; M G Peters; F Torriani; J Andersen; J S Currier Journal: J Acquir Immune Defic Syndr Date: 2010-10 Impact factor: 3.731
Authors: George K Siberry; Kunjal Patel; Russell B Van Dyke; Rohan Hazra; Sandra K Burchett; Stephen A Spector; Mary E Paul; Jennifer S Read; Andrew Wiznia; George R Seage Journal: J Acquir Immune Defic Syndr Date: 2011-07-01 Impact factor: 3.731
Authors: Abdel G Babiker; Sean Emery; Gerd Fätkenheuer; Fred M Gordin; Birgit Grund; Jens D Lundgren; James D Neaton; Sarah L Pett; Andrew Phillips; Giota Touloumi; Michael J Vjechaj Journal: Clin Trials Date: 2012-04-30 Impact factor: 2.486
Authors: Awachana Jiamsakul; Stephen J Kerr; Oon Tek Ng; Man Po Lee; Romanee Chaiwarith; Evy Yunihastuti; Kinh Van Nguyen; Thuy Thanh Pham; Sasisopin Kiertiburanakul; Rossana Ditangco; Vonthanak Saphonn; Benedict L H Sim; Tuti Parwati Merati; Wingwai Wong; Pacharee Kantipong; Fujie Zhang; Jun Yong Choi; Sanjay Pujari; Adeeba Kamarulzaman; Shinichi Oka; Mahiran Mustafa; Winai Ratanasuwan; Boondarika Petersen; Matthew Law; Nagalingeswaran Kumarasamy Journal: Trop Med Int Health Date: 2016-03-29 Impact factor: 2.622
Authors: H Samji; T E Taha; D Moore; A N Burchell; A Cescon; C Cooper; J M Raboud; M B Klein; M R Loutfy; N Machouf; C M Tsoukas; J S G Montaner; R S Hogg Journal: HIV Med Date: 2014-09-01 Impact factor: 3.180
Authors: Daniel J Skiest; Amy Krambrink; Zhaohui Su; Kevin R Robertson; David M Margolis Journal: J Acquir Immune Defic Syndr Date: 2008-12-01 Impact factor: 3.731
Authors: Meredith E Childers; Steven Paul Woods; Scott Letendre; J Allen McCutchan; Debralee Rosario; Igor Grant; Monica Rivera Mindt; Ronald J Ellis Journal: J Neurovirol Date: 2008-11 Impact factor: 2.643